Serina Therapeutics Secures Up To $30M From The Sale Of Common Stock And Pre-Funded Warrants Priced At A Combined Price Of $2.25 In A Private Placement To Support Registrational Trial Of SER-252 Parkinson's Treatment

Serina Therapeutics has secured up to $30 million through a private placement of common stock and pre-funded warrants priced at $2.25 per share, which is a 68% premium to the March 17, 2026 closing price. The financing includes a first tranche of $15 million expected to close on March 20, 2026, and a second tranche of up to $15 million. Additionally, the financing features 50% warrant coverage priced at $5 per share, which could raise an extra $33.3 million if exercised, extending the company's runway into the second half of 2027. The proceeds will support the registrational trial of SER-252 for Parkinson's treatment.